GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » Other Gross PPE

Coherus BioSciences (FRA:8C5) Other Gross PPE : €6.5 Mil (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Other Gross PPE?

Coherus BioSciences's Other Gross PPE for the quarter that ended in Mar. 2024 was €6.5 Mil.

Coherus BioSciences's quarterly Other Gross PPE declined from Sep. 2023 (€8.3 Mil) to Dec. 2023 (€7.4 Mil) and declined from Dec. 2023 (€7.4 Mil) to Mar. 2024 (€6.5 Mil).

Coherus BioSciences's annual Other Gross PPE increased from Dec. 2021 (€7.3 Mil) to Dec. 2022 (€10.2 Mil) but then declined from Dec. 2022 (€10.2 Mil) to Dec. 2023 (€7.4 Mil).


Coherus BioSciences Other Gross PPE Historical Data

The historical data trend for Coherus BioSciences's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Other Gross PPE Chart

Coherus BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.53 5.99 7.29 10.22 7.38

Coherus BioSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.62 8.66 8.34 7.38 6.48

Coherus BioSciences Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Coherus BioSciences (FRA:8C5) Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Coherus BioSciences (FRA:8C5) Headlines

No Headlines